Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA), has scheduled its Q1 2025 financial results announcement for Monday, May 12, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET to discuss the results. Investors can access the call via domestic (1-800-717-1738) or international (1-646-307-1865) numbers using Conference ID 53214. A live webcast will be available through the Investor Relations section of the company's website.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per l'ipertensione, la malattia renale cronica (CKD) e l'apnea ostruttiva del sonno (OSA), ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call alle 16:30 ET per discutere i risultati. Gli investitori potranno partecipare alla chiamata tramite i numeri nazionali (1-800-717-1738) o internazionali (1-646-307-1865) utilizzando il Conference ID 53214. Sarà inoltre disponibile una diretta streaming nella sezione Investor Relations del sito web dell'azienda.
Mineralys Therapeutics (NASDAQ: MLYS), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para hipertensión, enfermedad renal crónica (ERC) y apnea obstructiva del sueño (AOS), ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, después del cierre del mercado.
La empresa realizará una conferencia telefónica a las 4:30 p.m. ET para discutir los resultados. Los inversores pueden acceder a la llamada a través de los números nacionales (1-800-717-1738) o internacionales (1-646-307-1865) utilizando el ID de conferencia 53214. También estará disponible una transmisión en vivo a través de la sección de Relaciones con Inversores en el sitio web de la compañía.
Mineralys Therapeutics (NASDAQ: MLYS)는 고혈압, 만성 신장 질환(CKD), 폐쇄성 수면 무호흡증(OSA) 치료를 전문으로 하는 임상 단계의 생명공학 제약 회사로, 2025년 5월 12일 월요일 장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다.
회사는 동부 표준시 오후 4시 30분에 실적에 대해 논의하는 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 국내 번호(1-800-717-1738) 또는 국제 번호(1-646-307-1865)를 통해 컨퍼런스 ID 53214를 사용하여 콜에 참여할 수 있습니다. 회사 웹사이트의 투자자 관계 섹션에서 라이브 웹캐스트도 제공됩니다.
Mineralys Therapeutics (NASDAQ : MLYS), une société biopharmaceutique en phase clinique spécialisée dans les traitements de l'hypertension, de la maladie rénale chronique (MRC) et de l'apnée obstructive du sommeil (AOS), a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025, après la clôture du marché.
La société organisera une conférence téléphonique à 16h30 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via les numéros nationaux (1-800-717-1738) ou internationaux (1-646-307-1865) en utilisant l'ID de conférence 53214. Un webcast en direct sera disponible dans la section Relations Investisseurs du site web de la société.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen von Bluthochdruck, chronischer Nierenerkrankung (CKD) und obstruktiver Schlafapnoe (OSA) spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über nationale (1-800-717-1738) oder internationale (1-646-307-1865) Nummern mit der Konferenz-ID 53214 teilnehmen. Ein Live-Webcast wird über den Bereich Investor Relations auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.
| Monday, May 12th @ 4:30 p.m. ET | |
| Domestic: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 53214 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) report Q1 2025 earnings?
How can I join the Mineralys Therapeutics Q1 2025 earnings call?
What diseases does Mineralys Therapeutics (MLYS) focus on treating?
What time is the Mineralys Therapeutics (MLYS) Q1 2025 earnings call?
